REG - Hemogenyx Pharma Plc - Institutional Investment

Hemogenyx PharmaceuticalsAnnouncement

11/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241111:nRSK6146La&default-theme=true

RNS Number : 6146L  Hemogenyx Pharmaceuticals PLC  11 November 2024

11 November 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Institutional Investment of £600,000

Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group focused
on developing new therapies for blood diseases, is pleased to announce that it
was approached by an institutional investor and that this investor has
subscribed £600,000, for the issue of 60,000,000 new Ordinary Shares at 1p
per share.

The net proceeds of this subscription will be dedicated to the imminent
commencement of the  Phase I clinical trials for the Company's Chimeric
Antigen Receptor T-cell therapy ("HEMO-CAR-T" or "HG-CT-1"), aimed at treating
acute myeloid leukemia ("AML").

The Company will keep the Market informed of future developments as trials
commence and develop.

An application is being made to the Main Market of the London Stock Exchange
Main Market, and admission of the Subscription Shares to trading is expected
on or around 15 November 2024 ("Admission"). The Subscription Shares will rank
pari passu with the Company's existing Ordinary Shares.

 

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented: "We are greatly encouraged by the confidence shown by our new
institutional investor and are grateful for their support in advancing our
mission to bring innovative treatments to patients with acute myeloid
leukemia. This investment enables us to take a significant step forward with
our HEMO-CAR-T program, moving into clinical trials and bringing us closer to
providing a new therapeutic option for patients facing this aggressive
disease."

 

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
1,401,815,988 ordinary shares. The Company does not hold any shares in
treasury. The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the Company, under the
Disclosure Guidance and Transparency Rules.

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

 

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEBLFFZFLBFBF